Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03243461 | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)(HIT-HGG-2013) | unknown | Phase 3 | 167 | University of GöttingenOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT02892708 | Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over(CSA) | completed | Phase 3 | 107 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects(INTACT) | terminated | Phase 3 | 19 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | terminated | Phase 3 | 40 | AbbVieINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT04829097 | Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma | unknown | Phase 3 | 80 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | completed | Phase 2 / Phase 3 | 88 | Sahlgrenska University HospitalOTHER | 2 | Mar 18, 2021 | clinicaltrials |
| NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | completed | Phase 3 | 592 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04536649 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | unknown | Phase 3 | 369 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04277221 | ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) | unknown | Phase 3 | 118 | Safe Save Medical Cell Sciences & Technology Co.,Ltd.INDUSTRY | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT03722355 | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma | completed | Phase 3 | 712 | Radiation Therapy Oncology GroupNETWORK | 0 | Nov 12, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 637 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT02511405 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)(GLOBE) | completed | Phase 3 | 252 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 3 | Oct 23, 2018 | clinicaltrials |
| NCT03633552 | Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma | unknown | Phase 3 | 62 | Mashhad University of Medical SciencesOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT01765088 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02629757 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas(β-elemene) | unknown | Phase 3 | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma(ACT IV) | completed | Phase 3 | 745 | Celldex TherapeuticsINDUSTRY | 24 | Jan 16, 2018 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00943826 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | completed | Phase 3 | 921 | Hoffmann-La RocheINDUSTRY | 24 | Sep 25, 2017 | clinicaltrials |
| NCT01149109 | Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients(CeTeG) | completed | Phase 3 | 141 | University Hospital, BonnOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | completed | Phase 3 | 151 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | completed | Phase 3 | 700 | NovoCure Ltd.INDUSTRY | 12 | Apr 10, 2017 | clinicaltrials |
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma(REGAL) | completed | Phase 3 | 423 | AstraZenecaINDUSTRY | 10 | Dec 28, 2016 | clinicaltrials |
| NCT00088400 | Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors | completed | Phase 3 | 30 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | withdrawn | Phase 3 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01364064 | Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 1,153 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT02623231 | The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients(Cipralex&GBM) | unknown | Phase 2 / Phase 3 | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01450449 | Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme | completed | Phase 3 | 115 | International Atomic Energy AgencyOTHER_GOV | 14 | Mar 24, 2015 | clinicaltrials |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma(SAPPHIRE) | terminated | Phase 3 | 27 | Isarna Therapeutics GmbHINDUSTRY | 16 | Nov 14, 2014 | clinicaltrials |
| NCT00689221 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status(CENTRIC) | completed | Phase 3 | 545 | EMD SeronoINDUSTRY | 2 | Nov 4, 2014 | clinicaltrials |
| NCT01656980 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | unknown | Phase 3 | 236 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 3, 2012 | clinicaltrials |
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 3 | 236 | NovoCure Ltd.INDUSTRY | 7 | May 1, 2012 | clinicaltrials |
| NCT01167322 | Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas | completed | Phase 3 | 45 | NobelpharmaINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT01502241 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly(Methusalem) | completed | Phase 3 | 412 | Heidelberg UniversityOTHER | 2 | Dec 30, 2011 | clinicaltrials |
| NCT00076986 | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 3 | 300 | INSYS Therapeutics IncINDUSTRY | 6 | Jun 6, 2011 | clinicaltrials |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | completed | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2011 | clinicaltrials |
| NCT01308632 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | unknown | Phase 2 / Phase 3 | 30 | Grupo Español de Investigación en NeurooncologíaOTHER | 0 | Mar 4, 2011 | clinicaltrials |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy(Glass-Art) | terminated | Phase 3 | 9 | Bradmer Pharmaceuticals Inc.INDUSTRY | 0 | Feb 10, 2011 | clinicaltrials |
| NCT00224978 | Chloroquine for Treatment of Glioblastoma Multiforme | completed | Phase 3 | — | National Institute of Neurology and Neurosurgery, MexicoOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | withdrawn | Phase 3 | 323 | Xenova BiomedixINDUSTRY | 2 | Jan 7, 2009 | clinicaltrials |
| NCT00717210 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide(NOA-04) | completed | Phase 3 | 318 | Neuro-Oncology Working Group of the German Cancer SocietyNETWORK | 1 | Jul 17, 2008 | clinicaltrials |
Data updated 22 days agoSource updated May 11, 2023source: clinicaltrials